We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
130 hedge funds and large institutions have $1.1B invested in AbCellera Biologics in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
238% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $8.04M
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
5% more funds holding
Funds holding: 124 → 130 (+6)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.7% less ownership
Funds ownership: 40.68% → 39.97% (-0.7%)
32% less capital invested
Capital invested by funds: $1.63B → $1.1B (-$524M)
Holders
130
Holders Change
+6
Holders Change %
+4.84%
% of All Funds
2.05%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
28
Increased
41
Reduced
36
Closed
21
Calls
$27.1M
Puts
$8.04M
Net Calls
+$19.1M
Net Calls Change
-$5.55M
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$70.8M |
| 2 |
Lazard Asset Management
New York
|
+$27.4M |
| 3 |
Renaissance Technologies
New York
|
+$19.7M |
| 4 |
Millennium Management
New York
|
+$7.55M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$5.95M |
